Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...

Chronic urticaria (CU) is a dermatological condition characterized by recurrent wheals (hives), angioedema (deep tissue swelling), or both, persisting for over 6 weeks. 1 Unlike acute urticaria ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...